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Abstract
Background: Copeptin has recently been identified to be a stable surrogate marker for the unstable hormone
arginine vasopressin (AVP). Copeptin has been shown to correlate with disease severity in leptospirosis and
bacterial sepsis. Hyponatraemia is common in severe imported malaria and dysregulation of AVP release has been
hypothesized as an underlying pathophysiological mechanism. The aim of the present study was to evaluate the
performance of copeptin as a predictor of disease severity in imported malaria.
Methods: Copeptin was measured in stored serum samples of 204 patients with imported malaria that were
admitted to our Institute for Tropical Diseases in Rotterdam in the period 1999-2010. The occurrence of WHO
defined severe malaria was the primary end-point. The diagnostic performance of copeptin was compared to that
of previously evaluated biomarkers C-reactive protein, procalcitonin, lactate and sodium.
Results: Of the 204 patients (141 Plasmodium falciparum, 63 non-falciparum infection), 25 had severe malaria. The
Area Under the ROC curve of copeptin for severe disease (0.66 [95% confidence interval 0.59-0.72]) was
comparable to that of lactate, sodium and procalcitonin. C-reactive protein (0.84 [95% CI 0.79-0.89]) had a
significantly better performance as a biomarker for severe malaria than the other biomarkers.
Conclusions: C-reactive protein but not copeptin was found to be an accurate predictor for disease severity in
imported malaria. The applicability of copeptin as a marker for severe malaria in clinical practice is limited to
exclusion of severe malaria.
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Background
Arginine vasopressin (AVP), also known as the antidiure-
tic hormone, is a key hormone in maintaining fluid bal-
ance and vascular tone. Despite its clinical relevance,
measurement of mature AVP is difficult and subject to
(pre)analytical errors. Recently, copeptin, a 39-amino
acid glycopeptide that comprises the C-terminal part of
the AVP precursor was found to be a stable and sensitive
surrogate marker for AVP release [1,2]. In recent studies
in patients with bacterial sepsis but also in patients with
leptospirosis it was shown that copeptin levels correlate
well with disease severity and outcome when compared
to other commonly used biomarkers like C-reactive
protein (CRP) and more experimental biomarkers like
procalcitonin [3,4]. Copeptin levels may even be used as
a valuable tool to guide management of critically ill
patients [4]. Leptospirosis and bacterial sepsis are strik-
ingly similar to severe malaria in terms of case-fatality
rates and clinical presentation including the presence of
hyponatraemia [5-9]. Hyponatraemia was found to be
highly prevalent in severe malaria and suggested to be
the result of a dysregulated vasopressin release [6-8].
The present study, therefore, aimed to evaluate copep-
tin as a pathophysiologic predictor of disease severity in
patients with imported malaria. The diagnostic perfor-
mance of copeptin was compared to that of several pre-
viously validated biomarkers to provide the clinician with
the most accurate tool for clinical decision making in the
acute care setting. A reliable test, easily discriminating
severe from non-severe disease in malaria, would be
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clinically useful, especially in the setting of imported
malaria, given the observation that most clinicians in
non-endemic areas have little expertise with identifying
severe malaria but these patients require a rapid triage
for parenteral anti-malarials and intensive monitoring.
Methods
The Harbour Hospital is a 161-bed general hospital
located in Rotterdam, The Netherlands. It also harbours
the Institute for Tropical Diseases, which serves as a
national reference centre. In the period 1999-2010 more
than 500 cases of imported malaria were diagnosed. The
characteristics of the Rotterdam Malaria Cohort in the
period 1999-2008 were previously described [9]. For the
majority of these cases, demographic, clinical and labora-
tory data and serum samples were available. In the present
study copeptin and procalcitonin were retrospectively
measured in stored serum samples of 204 patients with
imported malaria. The tested serum samples were not
from consecutive patients entering this cohort but based
on availability. The occurrence of severe malaria was con-
sidered a primary end-point given the low case-fatality
rate of imported malaria in the Netherlands. Because
severe malaria can also occur in non-falciparum infections
(albeit rare in returning travellers), patients with non-falci-
parum infections were not excluded. This contrasts with
the design of many studies in patients with severe malaria
in regions of malaria endemicity where the severity criteria
are usually used as an entry criterion [10] and focus on
P. falciparum malaria. In the present study, the previously
validated biomarkers plasma lactate [11], procalcitonin
[12,13], sodium and CRP [9] were used as comparative
biomarkers for copeptin to evaluate its accuracy for use in
clinical practice to differentiate severe from non-severe
malaria.
Procedures
On admission, blood samples were taken for analysis of
the red blood cell count, haematocrit, white blood cell
count, platelet count, CRP, serum electrolytes, total biliru-
bin, serum creatinin, liver enzymes, and blood glucose. A
separate blood tube was drawn on admission for determi-
nation of plasma lactate, which was immediately analysed
after isolation of plasma. Malaria was diagnosed by QBC
(Quantitative Buffy Coat) analysis, by a rapid diagnostic
antigen test for malaria (Binax NOW® Malaria Test, Binax
Inc. Maine, USA) and by conventional microscopy of
stained thick and thin blood smears to identify the causa-
tive Plasmodium species. In case of Plasmodium falci-
parum infections, parasite density was determined. When
the parasitaemia was less than 0.5% infected erythrocytes,
parasites were counted per 100 leucocytes in thick smears.
When the parasitaemia was equal or higher than 0.5%
infected erythrocytes, infected erythrocytes were counted
in thin smear and expressed as a percentage of the total
erythrocytes. The number of parasites per microliter was
subsequently calculated from these data. Patients were
classified as having severe malaria if they met one or more
of the WHO criteria for severe malaria, as published [14].
Procalcitonin levels were determined in serum samples
using a commercially available EIA test (VIDAS BRAHMS
Procalcitonin, bioMérieux, Lyon, France). Normal serum
values for procalcitonin are < 0.1 ng/ml. Copeptin was
measured with a commercial sandwich immunolumino-
metric assay (Brahms Copeptin, Thermo Fisher Scientific,
Hennigsdorf/Berlin, Germany). Normal values for serum
copeptin are 1.70-11.25 pmol/L [2].
Statistical methods
Differences between patients with severe malaria, non-
severe P. falciparum malaria and non-severe non-
falciparum malaria were analysed with the Kruskall-Wallis
test followed by Dunn’s post-hoc tests. Two group com-
parisons were done by Student’s unpaired t-test, Student’s
unpaired t-test with Welch correction or with the non-
parametric Mann Whitney test depending on the distribu-
tion of the data. The diagnostic performance of each
biomarker was reported as sensitivity, specificity, positive
and negative predictive value for severe malaria and their
corresponding 95% confidence intervals. Youden’s index J
(J = sensitivity + specificity-1) was used to identify the
most appropriate cut-off point for each biomarker. Of
each test a Receiver Operating Characteristics (ROC)
curve, a graphical plot of sensitivity (true positive rate) ver-
sus 1-specificity (false positive rate), was constructed as a
summary statistic and the area under the ROC curve
(AUROC) and its corresponding 95% confidence intervals
were calculated. The AUROC of each of the biomarkers
was compared to that of copeptin in a pair-wise compari-
son with the method of DeLong et al. [15].
Results
Patient characteristics
In total, 204 travellers with imported malaria were
included in this study; 63 patients were diagnosed with a
non-falciparum infection (45 with Plasmodium vivax, 15
with Plasmodium ovale, three with Plasmodium malariae)
and 141 patients were diagnosed with P. falciparum infec-
tion. Of the patients with P. falciparum infections, 25
(17.7%) patients had severe malaria. There were no cases
of severe non-falciparum malaria. The infection was most
frequently acquired in Africa (n = 156), followed by Asia
(n = 27) and South America (n = 14). Thirty (14.7%)
patients reported adequate use of malaria chemoprophy-
laxis, 24 (11.8%) used it inadequately and 143 (70.1%)
patients did not use any chemoprophylaxis (data on pro-
phylaxis use were not available in seven patients). The
general characteristics of all patients are shown in Table 1.
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Characteristics of patients with severe malaria
Twenty-one of 25 patients (84.0%) with severe malaria
acquired a P. falciparum infection in West-Africa. The
others acquired severe malaria in East-Africa (n = 2),
South-East Asia (n = 1) and South-America (n = 1).
Twenty-four patients with severe malaria did not use
any form of malaria chemoprophylaxis and one patient
was using it inadequately. At admission to the intensive
care unit (ICU), the 25 patients with severe malaria all
fulfilled one or more of the severity criteria (Glasgow
Coma Score ≤ 11, n = 2; haematocrit < 0.20 L/L n = 5;
creatinine > 250 μmol/L n = 2; bilirubin > 50 μmol/L
n = 12; lactate > 5.0 mmol/L n = 5; hyperparasitaemia
> 5% n = 14; schizontaemia n = 14). The first arterial
blood gas analysis on the ICU showed a median bicar-
bonate level of 21 mmol/L (range 9-25 mmol/L) and a
median base excess of -2 mmol/L (range -18-3). The
median Glasgow Coma Scale score was 15 (range 11-
15). Two patients required mechanical ventilation. Two
patients were referred to another hospital for renal
replacement therapy because of persistent acute oliguric
renal insufficiency. Thirteen patients received exchange
transfusion as an adjunct therapy to parenteral anti-
malarial treatment. One case fatality was observed. The
laboratory results of travellers with severe malaria were
further characterized by significantly lower platelet
counts and haemoglobin levels and by significantly
higher plasma lactate, bilirubin and CRP levels com-
pared to patients with non-severe P. falciparum malaria
(Table 1).
Analysis of biomarkers for severe malaria
In order to evaluate the diagnostic accuracy of copeptin
for severe malaria, the performance of copeptin was com-
pared to that of sodium, CRP, lactate and procalcitonin.
Assuming that AUROCs are a measure of diagnostic accu-
racy, the performance of copeptin for severe malaria was
comparable to that of sodium, lactate and procalcitonin, as
Table 1 Characteristics of malaria patients at initial presentation
Severe malaria
[all P. falciparum]
(n = 25)
Non-severe
P. falciparum
(n = 116)
Non-severe
Non-falciparum
(n = 63)
P-value
Demographics
Age, years 44 (23-70) 41 (11-69) 38 (8-62) n.s.
Male, female, n (%) 15 (60), 10 (40) 92 (79), 24 (21) 44 (70), 19 (30) n.s.
Duration of complaints, n (%) 0.0905
Less than 1 week 16 (64) 83 (72) 31 (49)
1-2 weeks 8 (32) 20 (17) 15 (24)
3-4 weeks 0 (0) 8 (7) 5 (8)
More than 4 weeks 0 (0) 1 (1) 3 (5)
Vital signs on admission
Body temperature, °C 38.4 (35.7-40.6) 38.6 (35.7-41.0) 38.3 (36.0-41.2) n.s.
Pulse rate, beats per minute 108 (75-140)A < 0,001; B < 0,01 90 (68-130) 90 (58-138) 0.0005
Systolic blood pressure, mm Hg 118 (80-150) 120 (88-185) 120 (95-196) n.s.
Laboratory data on admission
Parasite density (parasites/μL) 284,005 (39,600-1,380,600) 22,657 (2-156,600) n.a. < 0.0001
C-reactive protein, mg/L 186 (71-407)A < 0,001; B < 0,001 95 (7-310) 83 (14-348) < 0.0001
Haemoglobin, mmol/L 7.8 (2.5-10.2)A < 0,05 8.5 (5.3-11.1) 8.3 (5.6-10.7) 0.0281
Haematocrit, L/L 0.37 (0.12-0.50)A < 0,05 0.41 (0.24-0.52) 0.39 (0.26-0.53) 0.0067
Leucocyte count, × 109/L 6.9 (2.5-18.5)A < 0,05 5.0 (2.2-12.6) 5.3 (1.9-11.0) 0.0361
Thrombocytes, × 109/L 36 (11-164)A < 0,001; B < 0,001 93 (16-385) 95 (10-292) 0.0004
Serum glucose, mmol/L 6.8 (4.1-8.8) 6.8 (4.4-26.0) 6.4 (4.2-22.1) n.s.
Serum sodium, mmol/L 131 (124-139)A < 0.05;B < 0,01 134 (122-141)C < 0,05 136 (127-141) < 0.0001
Serum creatinine, μmol/L 110 (70-1081)B < 0,001 97 (51-208)C < 0,05 91 (46-126) 0.0010
Serum urea, mmol/L 7.6 (3.8-55.8)A < 0,01; B < 0,01 5.2 (2.2-18.7) 5.1 (2.7-10.9) 0.0018
Plasma lactate, mmol/L 2,3 (1,0-5,8)A < 0,001; B < 0,05 1,4 (0,5-5,5) 1.7 (0.7-4.0) 0.0014
Procalcitonin, ng/mL 1.9 (0.9-42.3)A < 0.01 0.6 (0.0-11.2) 1.6 (0.0-42.6) 0.0057
Copeptin, pmol/L 22.9 (5.1-91.5) B < 0,05 13.9 (1.6-67.8) 12.0 (1.9-82.9) 0.0249
Duration hospitalisation, days 7 (3-13)A < 0,001; B < 0,001 5 (0-10)C < 0,001 2 (0-9) < 0.0001
Statistical analysis: Kruskall-Wallis (p-values in column) followed by Dunn’s post-hoc tests (p-values in superscript); n.s. denotes “not significant"; n.a. denotes “not
applicable”. A: severe malaria vs non-severe P. falciparum malaria; B: severe malaria vs non-severe non-falciparum malaria; C: non-severe P. falciparum malaria vs
non-severe non-falciparum malaria. Comparison of parasite density was calculated for P. falciparum infections only (Mann Whitney test)
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is shown in Figure 1. The AUROC of copeptin did not sta-
tistically differ from the AUROC of sodium, lactate and
procalcitonin in a pair-wise comparison (Table 2). As
shown in Figure 1 and Table 2, CRP had a significantly
better performance than either copeptin, sodium and lac-
tate for prediction of severe malaria but its usefulness in
clinical practice is probably limited. For illustration, when
a hypothetical decision rule for severe malaria was created
solely based on a CRP cut-off level of ≥ 155 mg/L, 10 of
62 (or 16.1%) evaluable patients with non-falciparum dis-
ease and 26 of 116 (or 22.4%) evaluable patients with
uncomplicated P. falciparum would have been falsely diag-
nosed as having severe malaria. In contrast, the diagnosis
severe malaria would not have been considered in 5 of
24 (20.8%) evaluable patients with severe disease. Addition
of either lactate, sodium or copeptin as a secondary selec-
tion criterion to the prediction rule did not result in a
proper identification of all patients with severe disease on
admission. Only after adding procalcitonin (at a cut-off of
≥ 0.9 ng/mL) as a secondary selection criterion to the pre-
diction rule, all evaluable patients with severe malaria
would have been correctly identified on admission (Addi-
tional file 1: Figure S1). However, still nine of 29 evaluable
patients with non-severe P. falciparum malaria and 10 of
15 evaluable patients with non-severe, non-falciparum
malaria would have been falsely diagnosed with severe
malaria, respectively (Additional file 1: Figure S1).
Analysis of biomarkers in relation to the number of
severity criteria in patients with severe disease
When focusing on the 25 patients with severe malaria, 11
patients fulfilled a single criterion for severe malaria on
admission, 11 patients fulfilled two malaria severity cri-
teria, 2 patients fulfilled 3 malaria severity criteria and one
patient fulfilled 4 malaria severity criteria on admission to
the ICU, respectively. As a consequence of this distribu-
tion a proper stratification by numbers of malaria severity
criteria present on admission was not feasible. When the
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Figure 1 Receiver Operating Curves (ROC) characteristics of the diagnostic performance of copeptin for severe P. falciparum malaria,
compared to that of sodium, lactate, CRP and procalcitonin. The ROC curve is a graph of sensitivity (true positive fraction) plotted against
1-specificity (false positive fraction). The performance of a diagnostic variable can be quantified by calculating the area under the ROC curve
(AUROC). The ideal test would have an AUROC of 1, whereas a random guess would have an AUROC of 0.5. The results of the pair-wise
comparison of ROC curves are shown (with copeptin ROC curve as comparator). a. copeptin vs sodium (n = 204 pairs, p-value not significant); b.
copeptin vs lactate (n = 124 pairs, p-value not significant); c. copeptin vs CRP (n = 202 pairs, p = 0.02); d. copeptin vs procalcitonin (n = 70 pairs,
p-value not significant). The copeptin graphs are not all identical due to missing values in pair-wise comparisons.
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severe malaria patients fulfilling a single malaria severity
criterion on admission were compared to the patients with
more than one criterion for severe malaria on admission,
only for the biomarker plasma lactate a statistically signifi-
cant difference was found (1.8 ± 0.6 versus 3.3 ± 1.6
mmol/L, p = 0.0042). See Additional file 2: Table S1 for
further details.
Discussion
In the present study, the diagnostic performance of several
biomarkers for severe malaria was evaluated. In contrast
to studies in patients with severe bacterial sepsis [3] and
severe leptospirosis [4], copeptin was not found to be a
more accurate marker to predict severe disease in malaria
than the previously validated biomarkers procalcitonin,
sodium, and lactate. This may suggest that the major clini-
cal manifestations of severe bacterial sepsis and leptospiro-
sis may follow other pathophysiologic pathways than in
patients with severe malaria. In the latter group of
patients, CRP had a clearly superior performance as com-
pared to the previously mentioned biomarkers including
copeptin. This finding is certainly of clinical relevance
since measurement of CRP protein is not only widely
available in industrialized countries but also readily avail-
able during night shifts in the acute care setting.
The current findings implicate that a CRP level above
155 mg/l predicts severe malaria with a sensitivity and spe-
cificity of 79% and 80%, respectively. However, the useful-
ness of CRP for the prediction of severe malaria in clinical
practice is probably limited. To illustrate this in more
detail: when a hypothetical decision rule for severe malaria
was constructed solely based on CRP and applied to the
current study population, 16% of the evaluable patients
with non-severe, non-falciparum malaria and 22% of the
evaluable patients with non-severe P. falciparum malaria
would have been falsely diagnosed as having severe
malaria, whereas the diagnosis severe malaria would not
have been considered in 21% of the evaluable patients
with severe disease. Addition of either copeptin, sodium or
lactate to the prediction rule did not result in a proper
identification of all patients with severe malaria. Only add-
ing procalcitonin ≥ 0.9 ng/mL as a secondary selection cri-
terion to the prediction rule would have correctly
identified all patients with severe malaria on admission at
the price of overestimating the disease severity in a consid-
erable number of patients with non-severe P. falciparum
malaria and patients with non-severe, non-falciparum
malaria, respectively. Applying this decision rule as a guide
to therapy would, therefore, still lead to a significant pro-
portion of malaria patients receiving more intensive moni-
toring and treatment than strictly necessary.
In addition, there may be another pitfall with CRP-based
decision rules in malaria. As is known from studies in
patients with severe malaria, co-infections may occur fre-
quently in patients with malaria, which in itself may lead
to a rise in CRP levels, irrespective of the malaria disease
severity. For example, in a large cohort of 400 cases of
imported severe malaria, 96 first episodes of co-infection
were seen, in particular pneumonia (n = 61), bacteraemia
(n = 18) and urinary tract infections (n = 12). Interestingly,
these episodes were related to both community-acquired
(n = 30) as well as nosocomial infections (n = 66) [16]. In
our study blood cultures of patients with severe malaria
did not demonstrate presence of co-existing bacteraemia
on admission.
These abovementioned observations underline the lim-
ited value of these biomarkers for a rapid diagnosis of
severe disease in the acute care setting in non-endemic
industrialized countries; as for now, a biomarker-based
decision rule can therefore certainly not replace the cur-
rent clinical evaluation. It is noteworthy that all currently
studied biomarkers were characterized by high negative
predictive values, which may be helpful for exclusion of
severe malaria on admission. The combined use of bio-
markers may look promising since they allow correct
identification of all patients with severe malaria but their
use in the current clinical practice is hampered by their
Table 2 Descriptive statistics of diagnostic accuracy of the various biomarkers for severe malaria
Copeptin
(pmol/L)
Sodium
(mmol/L)
Lactate
(mmol/L)
C-reactive protein
(mg/L)
Procalcitonin
(ng/mL)
Cut-off value 3 21 ≤ 132 ≥ 1.6 ≥ 155 ≥ 0.9
Youden’s index 0.33 0.44 0.41 0.59 0.51
Sensitivity 60 (39-78) 72 (50-87) 86 (64-96) 79 (57-92) 100 (68-100)
Specificity 73 (66-79) 72 (64-78) 56 (45-65) 80 (73-85) 51 (38-64)
Positive Predictive Value 31 (25-38) 26 (0.17-0.38) 29 (19-42) 35 (23-49) 28 (15-44)
Negative Predictive Value 93 (87-96) 95 (89-98) 95 (85-99) 97 (92-99) 100 (86-100)
Area Under the ROC curve 0.66 (0.59-0.72) 0.72 (0.66-0.78) 0.74 (0.66-0.81) 0.84 (0.79-0.89) 0.76 (0.65-0.86)
P-value* P = 0.4289 P = 0.6546 P = 0.0237 P = 0.6479
Data are given as mean (95% confidence interval)
*P-values of pair-wise comparison of ROC curves are given (with Copeptin ROC curve as comparator)
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poor positive predictive values and lack of prospective
validation.
In conclusion, copeptin was not found to be a good bio-
marker for severe malaria in imported malaria. Instead,
CRP appeared to be a more accurate predictor for disease
severity than the other investigated biomarkers. The main
clinical applicability of the current biomarkers or combi-
nation of biomarkers is probably limited to a rapid exclu-
sion of severe disease given their high negative predictive
values and low positive predictive values.
Additional material
Additional file 1: Figure S1 A two-step decision rule including the
combined use of C-reactive protein and Procalcitonin to identify all
patients with severe malaria on admission. Legend: SF = severe P.
falciparum malaria; NSF = non-severe P. falciparum malaria; NSNF = non-
severe, non-falciparum malaria; CRP = C-reactive protein; PCT =
Procalcitonin.
Additional file 2: Table S1 Impact of the number of severity criteria
on the level of the biomarker on admission in malaria patients with
severe disease.
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